These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9829758)

  • 1. Dipyridamole potentiates antipurine antifolate activity in the presence of hypoxanthine in tumor cells but not in normal tissues in vitro.
    Marshman E; Newell DR; Calvert AH; Dickinson AM; Patel HR; Campbell FC; Curtin NJ
    Clin Cancer Res; 1998 Nov; 4(11):2895-902. PubMed ID: 9829758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growth inhibition by dipyridamole in human lung cancer cell lines.
    Smith PG; Marshman E; Calvert AH; Newell DR; Curtin NJ
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):63-7. PubMed ID: 10598557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity.
    Smith PG; Thomas HD; Barlow HC; Griffin RJ; Golding BT; Calvert AH; Newell DR; Curtin NJ
    Clin Cancer Res; 2001 Jul; 7(7):2105-13. PubMed ID: 11448930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxanthine transport in human tumour cell lines: relationship to the inhibition of hypoxanthine rescue by dipyridamole.
    Marshman E; Taylor GA; Thomas HD; Newell DR; Curtin NJ
    Biochem Pharmacol; 2001 Feb; 61(4):477-84. PubMed ID: 11226382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell lines.
    Lu X; Errington J; Chen VJ; Curtin NJ; Boddy AV; Newell DR
    Clin Cancer Res; 2000 Jan; 6(1):271-7. PubMed ID: 10656458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective potentiation of lometrexol growth inhibition by dipyridamole through cell-specific inhibition of hypoxanthine salvage.
    Turner RN; Aherne GW; Curtin NJ
    Br J Cancer; 1997; 76(10):1300-7. PubMed ID: 9374375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport.
    Smith PG; Marshman E; Newell DR; Curtin NJ
    Br J Cancer; 2000 Feb; 82(4):924-30. PubMed ID: 10732767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells.
    Smith SG; Lehman NL; Moran RG
    Cancer Res; 1993 Dec; 53(23):5697-706. PubMed ID: 8242626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteosarcoma cells, resistant to methotrexate due to nucleoside and nucleobase salvage, are sensitive to nucleoside analogs.
    Cole PD; Smith AK; Kamen BA
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):111-6. PubMed ID: 12172974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of cell death following thymidylate synthase inhibition: 2'-deoxyuridine-5'-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole.
    Curtin NJ; Harris AL; Aherne GW
    Cancer Res; 1991 May; 51(9):2346-52. PubMed ID: 2015598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifolate drug interactions: enhancement of growth inhibition due to the antipurine 5,10-dideazatetrahydrofolic acid by the lipophilic dihydrofolate reductase inhibitors metoprine and trimetrexate.
    Galivan J; Nimec Z; Rhee M; Boschelli D; Oronsky AL; Kerwar SS
    Cancer Res; 1988 May; 48(9):2421-5. PubMed ID: 2965613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.
    Barnes MJ; Estlin EJ; Taylor GA; Aherne GW; Hardcastle A; McGuire JJ; Calvete JA; Lunec J; Pearson AD; Newell DR
    Clin Cancer Res; 1999 Sep; 5(9):2548-58. PubMed ID: 10499632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of p53 status on cellular sensitivity to antifolate drugs.
    Lu X; Errington J; Curtin NJ; Lunec J; Newell DR
    Clin Cancer Res; 2001 Jul; 7(7):2114-23. PubMed ID: 11448931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of HL-60 leukemia cell differentiation by the novel antifolate 5,10-dideazatetrahydrofolic acid.
    Sokoloski JA; Beardsley GP; Sartorelli AC
    Cancer Res; 1989 Sep; 49(17):4824-8. PubMed ID: 2758415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced alpha1-acid glycoprotein binding.
    Curtin NJ; Bowman KJ; Turner RN; Huang B; Loughlin PJ; Calvert AH; Golding BT; Griffin RJ; Newell DR
    Br J Cancer; 1999 Aug; 80(11):1738-46. PubMed ID: 10468290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs.
    Schultz RM; Chen VJ; Bewley JR; Roberts EF; Shih C; Dempsey JA
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):68-73. PubMed ID: 10598558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmentation of 5-fluorouracil cytotoxicity in human colon cancer cells by dipyridamole.
    Grem JL; Fischer PH
    Cancer Res; 1985 Jul; 45(7):2967-72. PubMed ID: 4005834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (6R)-5,10-Dideaza-5,6,7,8-tetrahydrofolic acid effects on nucleotide metabolism in CCRF-CEM human T-lymphoblast leukemia cells.
    Pizzorno G; Moroson BA; Cashmore AR; Beardsley GP
    Cancer Res; 1991 May; 51(9):2291-5. PubMed ID: 1707749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514.
    Schultz RM; Patel VF; Worzalla JF; Shih C
    Anticancer Res; 1999; 19(1A):437-43. PubMed ID: 10226579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dipyridamole potentiates adriamycin cytotoxicity by a mechanism other than inhibiting nucleoside uptake.
    Kusumoto H; Maehara Y; Anai H; Kumashiro R; Sugimachi K
    Anticancer Res; 1991; 11(4):1539-42. PubMed ID: 1746911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.